Valeant Pharmaceuticals (VRX) shares have fallen sharply in early trading today after the company announced that its Bausch + Lomb unit received Complete Response Letter (CRL) regarding its New Drug Application (NDA) seeking approval of latanoprostene bunod ophthalmic solution, 0.024%, an intraocular pressure-lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension. The CRL cited deficiencies observed during a Current Good Manufacturing Practice (CGMP) inspection at B+L's manufacturing site in Tampa, FL. The letter did not identify any safety or efficacy issues with the product.